Top in endocrinology: Setmelanotide reduces BMI; dangers of endocrine-disrupting chemicals

Results of a phase 2 trial showed that 89% of children and adults with hypothalamic obesity had a 5% or greater reduction in BMI after receiving setmelanotide over 16 weeks.

On average, adults had a 6% drop in BMI from baseline to 16 weeks, while children experienced an 18% drop.

Researchers also analyzed changes in maximal daily hunger scores among participants aged 12 years and older. They reported that mean maximal hunger scores were 2.9 points lower after 16 weeks of setmelanotide (Imcivree, Rhythm Pharmaceuticals) compared with baseline. It was the top story in endocrinology last week.

Another top story was about recent research on endocrine-disrupting chemicals (EDCs). According to a report from the Endocrine Society and International Pollutants Elimination Network, more than 24% of human diseases and disorders have been attributed to environmental factors, including EDCs, motivating concerns about EDC exposure and regulation.

Read these and more top stories in endocrinology below:

Setmelanotide lowers BMI by 5% or more for most people with hypothalamic obesity

Setmelanotide reduced BMI by at least 5% at 16 weeks among 89% of children and adults with hypothalamic obesity, according to findings from a phase 2 trial published in The Lancet Diabetes & Endocrinology. Read more.

A call for stronger EDC regulations as more studies establish links to human health

The past 10 years have seen rapid growth in research on how endocrine-disrupting chemicals affect humans. Read more.

Q&A: What people with diabetes should know about preventing kidney stones

Susan Weiner, MS, RDN, CDN, CDCES, FADCES, talks with Melanie Betz, MS, RD, CSR, FNKF, FAND, about preventing kidney stones through diet and nutrition. Read more.

Advances in AI could improve disease prediction, reduce provider stress

Explainable AI and systems that help providers with day-to-day tasks will allow experts to conduct more advanced research and make impactful changes in clinical care, according to two speakers at ENDO 2024. Watch video.

FLOW, SURMOUNT-OSA trial symposia among highlights at ADA Scientific Sessions

Presentations on the SURMOUNT-OSA, FLOW, INHALE-3 and TIGHT trials were among the many highlights at the American Diabetes Association’s 84th Scientific Sessions. Read more.